Welcome to our dedicated page for Waters SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Waters Corporation (NYSE: WAT) filings with the U.S. Securities and Exchange Commission (SEC), along with AI-generated summaries to help interpret key disclosures. Waters files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that cover its operations in analytical instruments, separations technologies, and software serving the life, materials, food, and environmental sciences.
For Waters, 10-K and 10-Q filings are central resources for understanding its business segments, end markets, and risk factors. These documents discuss topics such as the company’s role in pharmaceutical, industrial, and academic/government applications, as well as its global footprint in over 100 countries. AI summaries can highlight sections related to recurring revenue, instrument trends, and investments in areas like bioanalytical characterization and bioseparations.
Form 8-K filings are particularly important for tracking material events. Recent 8-Ks describe quarterly financial results, provide press releases as exhibits, and outline the definitive agreements for a Reverse Morris Trust transaction that will combine BD’s Biosciences and Diagnostic Solutions business with Waters. Other 8-Ks discuss the effectiveness of registration statements on Form S-4 and Form 10 related to that transaction and the mailing of a proxy statement/prospectus to Waters shareholders.
Investors can also use this page to locate information on governance matters and potential insider activity through ownership reports referenced in Waters’ filings. Real-time updates from EDGAR, combined with AI-powered explanations, are intended to make complex regulatory documents more accessible by summarizing key terms, conditions, and implications for WAT shareholders and stakeholders following Waters’ evolution in life science and diagnostics markets.
Waters Corporation SVP Jianqing Bennett reported equity awards that increase his direct ownership. He received stock options for 4,826 shares at an exercise price of $0.0000 per share and a grant of 986 shares of common stock, both described as grant or award acquisitions.
The common stock grant represents restricted stock units that convert into one share of common stock each upon vesting and settlement. Both the RSUs and the stock options will vest in four equal annual installments, with the first installment scheduled to vest on February 25, 2027, contingent on his continued service with the company.
Waters Corporation SVP & Chief Financial Officer Amol Chaubal received new equity awards. He was granted a stock option covering 7,125 shares and an award of 1,455 shares of common stock as a grant or other acquisition at no cash cost per share.
The 1,455-share grant represents restricted stock units that vest in four equal annual installments starting on February 25, 2027, and convert into common stock on a one-to-one basis at settlement. The 7,125-share stock option also vests in four equal annual installments beginning on February 25, 2027, contingent on his continued service.
Waters Corporation President and CEO Udit Batra reported equity awards that increase his direct holdings through compensation grants, not open-market trades. He received a stock option covering 25,283 shares at a grant price of $0.00 and a grant of 5,165 shares of common stock.
The 5,165-share grant represents restricted stock units that convert one-for-one into common stock and vest in four equal annual installments starting on February 25, 2027, subject to continued service. The 25,283-share stock option also vests in four equal annual installments beginning on February 25, 2027, and becomes exercisable on the same schedule.
Waters Corporation director Mark Vergnano reported equity awards rather than open-market trades. On February 25, 2026, he received a grant of stock options for 57 shares at an exercise price of $0.00 per share and an award of 23 shares of common stock, both as acquisitions.
The 23 common shares are restricted stock that remain subject to restrictions until February 9, 2027, when 100% of these restrictions lapse. All 57 shares underlying the stock option will vest and become exercisable on February 9, 2027. After these awards, he directly owns 4,540 shares of Waters common stock.
Waters Corp director Christopher A. Kuebler reported equity awards that increase his direct holdings. On February 25, 2026, he received a stock option for 57 shares at an exercise price of $0.00 per share and a grant of 23 shares of common stock at $0.00 per share.
The 23 common shares are subject to restrictions that lapse for all shares on February 9, 2027, and all 57 option shares vest and become exercisable on the same date. Following the stock grant, Kuebler directly owns 17,808 shares of Waters common stock.
Waters Corporation director Heather Knight reported awards of both stock options and restricted common shares. She received stock options for 57 shares at an exercise price of $0.0000 per share and a grant of 23 common shares, all as awards rather than open-market purchases.
The 23 common shares are subject to restrictions that lapse for all of the shares on February 9, 2027. All 57 option shares will vest and become exercisable on February 9, 2027. After these grants, her directly owned common shares total 1,149.070.
Waters Corporation director Jiang Wei reported receiving new equity awards. He acquired 23 shares of common stock at no cost, which are subject to restrictions that lapse in full on February 9, 2027. He was also granted a stock option for 57 shares that becomes fully exercisable on February 9, 2027. Both positions are held as direct ownership.
Waters Corporation director Pearl S. Huang reported receiving new equity awards. On February 25, 2026, she was granted stock options for 57 shares of common stock at an exercise price of $0.00 per share. All of these option shares will vest and become exercisable on February 9, 2027.
On the same date, she also acquired 23 shares of common stock at $0.00 per share as a restricted stock award. The restrictions on 100% of these shares are scheduled to lapse on February 9, 2027. Following these awards, her directly held common stock position increased to 3,276.3 shares.
Waters Corporation director Claire Fraser reported equity awards consisting of stock options and restricted common shares. On February 25, 2026, she was granted options for 877 shares of common stock at an exercise price of $0.0000 per share and 358 shares of common stock at no cost, both as awards rather than open-market purchases.
According to the disclosures, all 358 common shares are subject to restrictions that lapse on February 9, 2027. The 877 stock options will fully vest and become exercisable on the same date, aligning Fraser’s longer-term incentives with Waters’ future performance.
Waters Corporation director Richard H. Fearon reported awards of stock-based compensation. On February 25, 2026, he acquired a stock option covering 57 shares of common stock at an exercise price of $0.00 per share, which will vest and become exercisable on February 9, 2027.
He also received 23 shares of restricted common stock at no cost, subject to restrictions that lapse in full on February 9, 2027. Following these awards, he directly owned 2,302 shares of Waters common stock.